Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 1,680 Shares

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 1,680 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $50.00, for a total value of $84,000.00. Following the transaction, the chief executive officer now owns 2,187,060 shares in the company, valued at approximately $109,353,000. This trade represents a 0.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The stock was sold at an average price of $50.09, for a total value of $3,899,656.77.
• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The stock was sold at an average price of $50.07, for a total value of $1,990,332.57.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84.

Guardant Health Stock Up 3.1%

Shares of GH stock traded up $1.47 during trading hours on Monday, reaching $49.53. The company's stock had a trading volume of 2,926,769 shares, compared to its average volume of 2,130,739. The firm's 50 day simple moving average is $43.05 and its 200-day simple moving average is $41.25. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of -13.91 and a beta of 1.37. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company's revenue was up 20.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.46) EPS. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Piper Sandler reiterated an "overweight" rating and set a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stephens reiterated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. Scotiabank restated an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Finally, UBS Group raised their price objective on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $53.29.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the 4th quarter worth about $43,000. SVB Wealth LLC acquired a new position in Guardant Health during the 1st quarter worth about $54,000. Kimelman & Baird LLC acquired a new position in Guardant Health during the 4th quarter worth about $58,000. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Guardant Health during the 4th quarter worth about $61,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.